Avadel Pharmaceuticals is a specialty pharmaceutical company that develops and commercializes branded pharmaceutical products, including controlled-release therapeutic products based on its proprietary drug delivery technologies. The company's current portfolio of products and product candidates focuses on the urology, central nervous system (CNS)/sleep, and hospital markets. Its lead drug candidate, FT218, is an investigational formulation of sodium oxybate designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The Company is headquartered in Dublin, Ireland, with operations in St. Louis, Missouri, and Lyon, France.